Zentalis Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its CEO, Anthony Sun, MD, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its CEO, Anthony Sun, MD, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 p.m. ET. A live webcast will be available on the company’s website, with an archived version accessible afterwards.
Zentalis focuses on developing novel small molecule therapeutics targeting cancer pathways, including its lead program, ZN-c5, an oral selective estrogen receptor degrader for breast cancer. For more information, visit www.zentalis.com.
Details
News Market Reaction – ZNTL
The recorded move for ZNTL in the trading session of this news was +26.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.
A live webcast of the fireside chat will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the event, an archived webcast will be available on the Zentalis website.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. In addition to its lead program, ZN-c5, an oral selective estrogen receptor degrader (SERD) for estrogen-receptor-positive, HER2-negative breast cancer, the Company is developing a broad pipeline of oncology candidates, targeting areas of major unmet medical need. The Company has offices in New York and San Diego. For more information, please visit www.zentalis.com.
Contacts
Investor Contact:
Thomas Hoffmann
Solebury Trout
1.646.378.2931
thoffmann@soleburytrout.com
Media Contact:
Julia Deutsch
Solebury Trout
1.646.378.2967
jdeutsch@soleburytrout.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.